Article Text

PDF
Cryoglobulinaemic vasculitis: classification and clinical and therapeutic aspects
  1. Gerald S Braun1,
  2. Sophia Horster3,
  3. Katrin S Wagner4,
  4. Stephan Ihrler5,
  5. Holger Schmid2
  1. 1Division of Nephrology and Immunology, RWTH University, Aachen, Germany
  2. 2Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany
  3. 3Department of Dermatology, Ludwig-Maximilians-University, Munich, Germany
  4. 4Renal Unit, Department of Medicine II, Klinikum Rechts der Isar, Technical University, Munich, Germany
  5. 5Department of Pathology, Ludwig-Maximilians-University, Munich, Germany
  1. Correspondence to:
 Dr Holger Schmid
 Medizinische Poliklinik, Ludwig-Maximilians-Universität München, Pettenkoferstr 8a, 80336 Munich, Germany; holger.schmid{at}lrz.uni-muenchen.de

Abstract

Cryoglobulinaemia may cause cutaneous vasculitis and glomerulonephritis, potentially leading to end stage renal failure. An important proportion of cryoglobulinaemias are secondary to hepatitis C virus infection. Emerging antiviral treatment options offer a chance for causal therapy of these cases of cryoglobulinaemia. This review summarises the classification and clinical and therapeutic aspects of cryoglobulinaemic vasculitis and glomerulonephritis.

  • ANCA, antineutrophil cytoplasmic antibody
  • HBV, hepatitis B virus
  • HCV, hepatitis C virus
  • MPGN, membranoproliferative glomerulonephritis

Statistics from Altmetric.com

Footnotes

  • Funding: None.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.